Lasofoxifene

Revision as of 19:01, 4 September 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
Jump to navigation Jump to search


Lasofoxifene
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC28H31NO2
Molar mass413.55 or 563.64 (with tartrate)

WikiDoc Resources for Lasofoxifene

Articles

Most recent articles on Lasofoxifene

Most cited articles on Lasofoxifene

Review articles on Lasofoxifene

Articles on Lasofoxifene in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lasofoxifene

Images of Lasofoxifene

Photos of Lasofoxifene

Podcasts & MP3s on Lasofoxifene

Videos on Lasofoxifene

Evidence Based Medicine

Cochrane Collaboration on Lasofoxifene

Bandolier on Lasofoxifene

TRIP on Lasofoxifene

Clinical Trials

Ongoing Trials on Lasofoxifene at Clinical Trials.gov

Trial results on Lasofoxifene

Clinical Trials on Lasofoxifene at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lasofoxifene

NICE Guidance on Lasofoxifene

NHS PRODIGY Guidance

FDA on Lasofoxifene

CDC on Lasofoxifene

Books

Books on Lasofoxifene

News

Lasofoxifene in the news

Be alerted to news on Lasofoxifene

News trends on Lasofoxifene

Commentary

Blogs on Lasofoxifene

Definitions

Definitions of Lasofoxifene

Patient Resources / Community

Patient resources on Lasofoxifene

Discussion groups on Lasofoxifene

Patient Handouts on Lasofoxifene

Directions to Hospitals Treating Lasofoxifene

Risk calculators and risk factors for Lasofoxifene

Healthcare Provider Resources

Symptoms of Lasofoxifene

Causes & Risk Factors for Lasofoxifene

Diagnostic studies for Lasofoxifene

Treatment of Lasofoxifene

Continuing Medical Education (CME)

CME Programs on Lasofoxifene

International

Lasofoxifene en Espanol

Lasofoxifene en Francais

Business

Lasofoxifene in the Marketplace

Patents on Lasofoxifene

Experimental / Informatics

List of terms related to Lasofoxifene

Lasofoxifene (INN) (proposed tradename Fablyn) is a selective estrogen receptor modulator (SERM) which is under development for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.

In September 2005, Pfizer Inc. received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (Oporia®), a selective estrogen receptor modulator for the prevention of osteoporosis.

On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is now to be marketed under the tradename Fablyn.


References

External links

Template:Sex hormones

Template:WikiDoc Sources